Untitled-1
  • HOME
  • COMPANY
    • Research
    • Operation Teams
    • Scientific Advisors
  • TECHNOLOGY
    • TCR-T Cell
    • Clinical Application
  • PIPELINE
  • RESOURCES
    • News
    • Publications
    • Events
  • CONTACT
  • EnglishEnglish
    • EnglishEnglish
    • 中文 (中国)中文 (中国)

Home

  • TREATING VIRAL CANCER
    We are dedicated to the development of our proprietary cancer immunotherapy products, targeting hepatitis B virus-related hepatocellular carcinoma.
  • TECHNOLOGY
    Our library of virus-specific T cell receptors (TCR) has good coverage of the Asian population. Our TCR-T cell technology harnesses the patient’s own immune system to fight viral infections and related cancers.
  • LAB TO BEDSIDE
    Our collaborations with renowned research laboratories and hospitals help bring novel treatment strategies to patients. Our TCRs have been used clinically against viral diseases prevalent in Asia, such as chronic HBV infection-related hepatocellular carcinoma.

ABOUT US

Lion TCR is a clinical-stage biotechnology company, focused on the development of T cell receptor (TCR)-T cell therapy against life-threatening viral infections and viral-related cancers pertinent in Asia.

In Asia, more than 20% of new cancer cases per year are attributable to chronic infections. In particular, a large majority of hepatocellular carcinomas are due to chronic infection with the hepatitis B virus (HBV) which is endemic in Asia.

At Lion TCR, over a decade’s worth of basic research, product engineering and development, and pre-clinical/clinical assessment have culminated in our leading product that harnesses the power of a patient’s own immune system to eliminate HBV-related hepatocellular carcinoma.

Together with our world-renowned scientific advisors, we continue to develop novel immunotherapies against viral infections and their related cancers afflicting the Asian population.

LTCR-H1-1

TCR-Redirected T Cell Infusions to Prevent Hepatocellular Carcinoma Recurrence Post Liver Transplantation

LTCR-H1-2

TCR-Redirected T Cell Infusions to Treat Recurrent Hepatocellular Carcinoma Post Liver Transplantation

Read More »

Lion TCR Announces Data Presentation for its lead T-cell product, LioCyx-M at EASL Digital Liver Cancer Summit 2021

February 8, 2021Lion TCR

HSA approval for Phase 1 IND clinical trial for Lion TCR’s lead product LioCyx-M to characterize changes in liver cancer tumor microenvironment

January 18, 2021Lion TCR

EXPLORE OUR RESEARCH

LION TCR

2 Tukang Innovation Grove #09-04
Singapore 618305

T: +65 6813 0738


Facebook

FOR INQUIRIES

General
info@liontcr.com

Clinical Trials
clinicaltrials@liontcr.com

_

Investors
investors@liontcr.com

Career
career@liontcr.com

HOMECOMPANYRESOURCESTECHNOLOGYPIPELINECONTACT
© 2019 All rights reserved | Terms and Conditions | Privacy Policy